You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

398 Results
Drug
Other Name(s): Tarceva®
Oct 2022
Drug
Other Name(s): Firmagon®
Dec 1969
Drug
Other Name(s): Cosmegen®
Dec 1969
Drug
Dec 1969
Drug
Other Name(s): Zinecard®
Dec 1969
Drug
Other Name(s): Xgeva®; Wyost™
Sep 2024
Drug
Other Name(s): Halaven® (Eisai)
Jan 2018
Drug
Other Name(s): Xtandi®
Dec 1969
Drug
Other Name(s): Tafinlar®
Dec 1969
Drug
Other Name(s): Darzalex®
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative

Pages